Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1

Jean De La Croix Ndong, Alexander J. Makowski, Sasidhar Uppuganti, Guillaume Vignaux, Koichiro Ono, Daniel S. Perrien, Simon Joubert, Serena R. Baglio, Donatella Granchi, David A. Stevenson, Jonathan J. Rios, Jeffry S. Nyman, Florent Elefteriou

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Individuals with neurofibromatosis type-1 (NF1) can manifest focal skeletal dysplasias that remain extremely difficult to treat. NF1 is caused by mutations in the NF1 gene, which encodes the RAS GTPase-activating protein neurofibromin. We report here that ablation of Nf1 in bone-forming cells leads to supraphysiologic accumulation of pyrophosphate (PP i), a strong inhibitor of hydroxyapatite formation, and that a chronic extracellular signal-regulated kinase (ERK)-dependent increase in expression of genes promoting PP i synthesis and extracellular transport, namely Enpp1 and Ank, causes this phenotype. Nf1 ablation also prevents bone morphogenic protein-2-induced osteoprogenitor differentiation and, consequently, expression of alkaline phosphatase and PP i breakdown, further contributing to PP i accumulation. The short stature and impaired bone mineralization and strength in mice lacking Nf1 in osteochondroprogenitors or osteoblasts can be corrected by asfotase- α enzyme therapy aimed at reducing PP i concentration. These results establish neurofibromin as an essential regulator of bone mineralization. They also suggest that altered PP i homeostasis contributes to the skeletal dysplasias associated with NF1 and that some of the NF1 skeletal conditions could be prevented pharmacologically.

Original languageEnglish (US)
Pages (from-to)904-910
Number of pages7
JournalNature Medicine
Volume20
Issue number8
DOIs
StatePublished - 2014

Fingerprint

Physiologic Calcification
Neurofibromatosis 1
Bone Development
Bone
Neurofibromin 1
Ablation
Genes
GTPase-Activating Proteins
Osteoblasts
Extracellular Signal-Regulated MAP Kinases
Durapatite
Neurofibromatosis 1 Genes
Enzyme Therapy
Alkaline Phosphatase
Bone and Bones
Homeostasis
Enzymes
Phenotype
Gene Expression
Mutation

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

De La Croix Ndong, J., Makowski, A. J., Uppuganti, S., Vignaux, G., Ono, K., Perrien, D. S., ... Elefteriou, F. (2014). Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1. Nature Medicine, 20(8), 904-910. https://doi.org/10.1038/nm.3583

Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1. / De La Croix Ndong, Jean; Makowski, Alexander J.; Uppuganti, Sasidhar; Vignaux, Guillaume; Ono, Koichiro; Perrien, Daniel S.; Joubert, Simon; Baglio, Serena R.; Granchi, Donatella; Stevenson, David A.; Rios, Jonathan J.; Nyman, Jeffry S.; Elefteriou, Florent.

In: Nature Medicine, Vol. 20, No. 8, 2014, p. 904-910.

Research output: Contribution to journalArticle

De La Croix Ndong, J, Makowski, AJ, Uppuganti, S, Vignaux, G, Ono, K, Perrien, DS, Joubert, S, Baglio, SR, Granchi, D, Stevenson, DA, Rios, JJ, Nyman, JS & Elefteriou, F 2014, 'Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1', Nature Medicine, vol. 20, no. 8, pp. 904-910. https://doi.org/10.1038/nm.3583
De La Croix Ndong J, Makowski AJ, Uppuganti S, Vignaux G, Ono K, Perrien DS et al. Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1. Nature Medicine. 2014;20(8):904-910. https://doi.org/10.1038/nm.3583
De La Croix Ndong, Jean ; Makowski, Alexander J. ; Uppuganti, Sasidhar ; Vignaux, Guillaume ; Ono, Koichiro ; Perrien, Daniel S. ; Joubert, Simon ; Baglio, Serena R. ; Granchi, Donatella ; Stevenson, David A. ; Rios, Jonathan J. ; Nyman, Jeffry S. ; Elefteriou, Florent. / Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1. In: Nature Medicine. 2014 ; Vol. 20, No. 8. pp. 904-910.
@article{d905b2337a974fb8aa87c338f6317f4e,
title = "Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1",
abstract = "Individuals with neurofibromatosis type-1 (NF1) can manifest focal skeletal dysplasias that remain extremely difficult to treat. NF1 is caused by mutations in the NF1 gene, which encodes the RAS GTPase-activating protein neurofibromin. We report here that ablation of Nf1 in bone-forming cells leads to supraphysiologic accumulation of pyrophosphate (PP i), a strong inhibitor of hydroxyapatite formation, and that a chronic extracellular signal-regulated kinase (ERK)-dependent increase in expression of genes promoting PP i synthesis and extracellular transport, namely Enpp1 and Ank, causes this phenotype. Nf1 ablation also prevents bone morphogenic protein-2-induced osteoprogenitor differentiation and, consequently, expression of alkaline phosphatase and PP i breakdown, further contributing to PP i accumulation. The short stature and impaired bone mineralization and strength in mice lacking Nf1 in osteochondroprogenitors or osteoblasts can be corrected by asfotase- {\^I}± enzyme therapy aimed at reducing PP i concentration. These results establish neurofibromin as an essential regulator of bone mineralization. They also suggest that altered PP i homeostasis contributes to the skeletal dysplasias associated with NF1 and that some of the NF1 skeletal conditions could be prevented pharmacologically.",
author = "{De La Croix Ndong}, Jean and Makowski, {Alexander J.} and Sasidhar Uppuganti and Guillaume Vignaux and Koichiro Ono and Perrien, {Daniel S.} and Simon Joubert and Baglio, {Serena R.} and Donatella Granchi and Stevenson, {David A.} and Rios, {Jonathan J.} and Nyman, {Jeffry S.} and Florent Elefteriou",
year = "2014",
doi = "10.1038/nm.3583",
language = "English (US)",
volume = "20",
pages = "904--910",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1

AU - De La Croix Ndong, Jean

AU - Makowski, Alexander J.

AU - Uppuganti, Sasidhar

AU - Vignaux, Guillaume

AU - Ono, Koichiro

AU - Perrien, Daniel S.

AU - Joubert, Simon

AU - Baglio, Serena R.

AU - Granchi, Donatella

AU - Stevenson, David A.

AU - Rios, Jonathan J.

AU - Nyman, Jeffry S.

AU - Elefteriou, Florent

PY - 2014

Y1 - 2014

N2 - Individuals with neurofibromatosis type-1 (NF1) can manifest focal skeletal dysplasias that remain extremely difficult to treat. NF1 is caused by mutations in the NF1 gene, which encodes the RAS GTPase-activating protein neurofibromin. We report here that ablation of Nf1 in bone-forming cells leads to supraphysiologic accumulation of pyrophosphate (PP i), a strong inhibitor of hydroxyapatite formation, and that a chronic extracellular signal-regulated kinase (ERK)-dependent increase in expression of genes promoting PP i synthesis and extracellular transport, namely Enpp1 and Ank, causes this phenotype. Nf1 ablation also prevents bone morphogenic protein-2-induced osteoprogenitor differentiation and, consequently, expression of alkaline phosphatase and PP i breakdown, further contributing to PP i accumulation. The short stature and impaired bone mineralization and strength in mice lacking Nf1 in osteochondroprogenitors or osteoblasts can be corrected by asfotase- α enzyme therapy aimed at reducing PP i concentration. These results establish neurofibromin as an essential regulator of bone mineralization. They also suggest that altered PP i homeostasis contributes to the skeletal dysplasias associated with NF1 and that some of the NF1 skeletal conditions could be prevented pharmacologically.

AB - Individuals with neurofibromatosis type-1 (NF1) can manifest focal skeletal dysplasias that remain extremely difficult to treat. NF1 is caused by mutations in the NF1 gene, which encodes the RAS GTPase-activating protein neurofibromin. We report here that ablation of Nf1 in bone-forming cells leads to supraphysiologic accumulation of pyrophosphate (PP i), a strong inhibitor of hydroxyapatite formation, and that a chronic extracellular signal-regulated kinase (ERK)-dependent increase in expression of genes promoting PP i synthesis and extracellular transport, namely Enpp1 and Ank, causes this phenotype. Nf1 ablation also prevents bone morphogenic protein-2-induced osteoprogenitor differentiation and, consequently, expression of alkaline phosphatase and PP i breakdown, further contributing to PP i accumulation. The short stature and impaired bone mineralization and strength in mice lacking Nf1 in osteochondroprogenitors or osteoblasts can be corrected by asfotase- α enzyme therapy aimed at reducing PP i concentration. These results establish neurofibromin as an essential regulator of bone mineralization. They also suggest that altered PP i homeostasis contributes to the skeletal dysplasias associated with NF1 and that some of the NF1 skeletal conditions could be prevented pharmacologically.

UR - http://www.scopus.com/inward/record.url?scp=84907655164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907655164&partnerID=8YFLogxK

U2 - 10.1038/nm.3583

DO - 10.1038/nm.3583

M3 - Article

VL - 20

SP - 904

EP - 910

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 8

ER -